Adrienne A. Tymiak
Papers
1
Total Citations
37
H-Index
1
About
Adrienne A. Tymiak is a pioneering figure in pharmaceutical bioanalysis, whose work has fundamentally shaped how drug candidates are evaluated for metabolic stability. Her key research areas encompass high-throughput mass spectrometry, drug metabolism, and pharmaceutical profiling—fields where she has driven transformative methodological advances. Tymiak's most notable contribution is the development of the "MetFast" assay, an automated high-throughput liquid chromatography–mass spectrometry process that rapidly assesses the metabolic stability of potential drug candidates by measuring their susceptibility to cytochrome P450-mediated first-pass metabolism. This innovation, detailed in her highly cited 2007 paper (37 citations), revolutionized early-stage drug discovery by enabling researchers to quickly identify compounds with poor pharmacokinetic profiles, thereby accelerating the selection of viable drug leads. Beyond this landmark work, Tymiak has been instrumental in advancing analytical techniques that bridge the gap between chemistry and biology, making her a respected authority in the pharmaceutical industry. Her contributions have not only enhanced the efficiency of drug development pipelines but also set new standards for integrating automation and mass spectrometry into routine pharmaceutical profiling.
Research Focus
Key Achievements
Top Papers
- 1